Asianet Newsable on MSN
Armata Pharmaceuticals Stock Soars To Record High After Phage Therapy Data In Deadly Infection Trial; Retail Traders Pile In
The company’s bacteriophage therapy AP-SA02 achieved an 88% response rate in a Phase 2a trial for Staphylococcus aureus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback